Medibio Limited
SYDNEY, Australia and MINNEAPOLIS, Jan. 10, 2018 (GLOBE NEWSWIRE) -- Medibio Limited (MEB or the Company ) (ASX:MEB) (OTCQB:MDBIF) has received a Certificate of Compliance certifying that the Company's Quality Management System complies with the requirements of ISO 13485. This also includes conformance with the Canadian Medical Device Conformity Assessment System (CMDCAS).
The certification was issued by DQS Med, the Notified Body appointed to assess Medibio's submission for CE Mark. It signifies that Medibio has established a comprehensive quality system for the design and manufacturing of medical devices. ISO 13485 is recognized internationally as a universal measure of quality and is a critical prerequisite to securing CE Mark and other regulatory certifications.
"This is an major milestone for the Company," said Medibio's CEO & Managing Director, Mr. Jack Cosentino. "This accomplishment reflects the work of all individuals within the organization who all believe that this achievement of ISO certification echoes Medibio's commitment to the highest level of quality management and to operational and production excellence."
Following receipt of ISO certification, Medibio reaffirms its expectation of gaining CE Mark shortly.
About Medibio Limited
Medibio (ASX:MEB) (OTCQB:MDBIF) is a mental health technology company that has pioneered the use of objective biometrics to assist in the screening, diagnosing, monitoring and management of depression and other mental health conditions. The company was founded in Australia, with offices located in Melbourne (Vic), and U.S. offices in Minneapolis, MN. Medibio is listed on the Australian Securities Exchange Ltd and trades on the OTCQB Venture Market. Investors can find additional information on www.otcmarkets.com and www.asx.com.au.
Further Information: Website: www.medibio.com.au
Medibio Shareholder Enquiries:
Investor Relations
Medibio Limited
info@medibio.com.au
T: +1 (952) 222-0551
Australian Media Enquiries:
Peter Taylor
NWR Communications
peter@nwrcommunications.com.au
T: +61 (0) 412 036 231
WEB:http://medibio.com
Information om Globenewswire
Følg pressemeddelelser fra Globenewswire
Skriv dig op her, og modtag pressemeddelelser på e-mail. Indtast din e-mail, klik på abonner, og følg instruktionerne i den udsendte e-mail.
Flere pressemeddelelser fra Globenewswire
Trifork Group AG25.6.2025 08:09:03 CEST | Press release
36/2025・Trifork Group: Reporting of transactions made by persons discharging managerial responsibilities
Norsk Hydro25.6.2025 08:00:47 CEST | Press release
Repeat: Norsk Hydro: Hydro's second quarter results 2025
LIfT BioSciences25.6.2025 08:00:00 CEST | Press release
LIfT BioSciences Expands U.S. Footprint with New Facility at Portal Innovations, Houston Helix Park
FLSmidth A/S25.6.2025 07:55:13 CEST | Press release
Launch of previously announced share buy-back programme of up to DKK 1.4 billion
Gabriel Holding A/S25.6.2025 07:36:50 CEST | Pressemeddelelse
Gabriel Holding A/S opjusterer forventningerne til regnskabsåret 2024/25 for de fortsættende aktiviteter
I vores nyhedsrum kan du læse alle vores pressemeddelelser, tilgå materiale i form af billeder og dokumenter samt finde vores kontaktoplysninger.
Besøg vores nyhedsrum